Gimv

Gimv is a European investment company with over three decades of experience in private equity and venture capital. Gimv is listed on NYSE Euronext Brussels. Gimv currently manages around 1.8 billion EUR (including third party funds) of investments in 85 portfolio companies, which jointly realise a turnover of more than EUR 6 billion and employ over 28,000 professionals. As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are: Consumer 2020, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv’s home markets of the Benelux, France and Germany and can count on an extended international network of experts. More information on Gimv can be found on [www.gimv.com].

Barbara Arnst

Partner

JA

Jelle Assink

Associate

GB

Guillame Bardy

Partner

Guillaume Bardy

Partner

Ronald Bartel

Partner - Head Gimv Germany

FB

Ferdinand Becker

Associate

Patrick Van Beneden

Associate Partner

KB

Koen Bouckaert

Managing Partner

ND

Nicolas De Bruyne

Principal

Kristof Vande Capelle

CFO

Anne Caron

Partner

RC

Rishabh Chawla

Associate

Koen Dejonckheere

CEO

Dirk Dewals

Managing Partner and Head Connected Consumer

Bart Diels

Managing Partner

PF

Patrick Franken

Partner

TG

Thomas Goudriaan

Associate

Philipp von Hammerstein

Partner

TH

Thomas Harth

Associate

LH

Lisa Hengerer

Principal

Arie Hooimeijer

Partner

FH

Florian Hötzl

Associate

DJ

Dirk Jonkman

Associate

AJ

Andreas Jurgeit

Partner

Maxence Kasper

Principal

Hidde Van Kerckhoven

Principal

Gert Kerkstoel

Partner

KK

Kevin Klein

Principal

CK

Christoph Kocher

Associate

Elderd Land

Partner

FD

Frank De Leenheer

Investor Relations and Corporate Communications Manager

Gautier Lefebvre

Partner

Guy Mampaey

Partner

Erik Mampaey

Managing Partner

Maja Markovic

Partner

SM

Stéphanie Massart

Associate

Nick Medaer

Partner

Ruben Monballieu

Partner

Eric de Montgolfier

Partner and Head of Gimv France

Sven Oleownik

Partner

DD

David De Peuter

Principal

HP

Hadrien Pigot

Associate

Rombout Poos

Partner

Christophe Van Quickenborne

Partner

MR

Morgane Renault

Associate

FR

François-Xavier Rico

Associate

CR

Clémence Robles

Principal

Nd

Nicolas de Saint-Laon

Partner and Head of GIMV France

CS

Catharina Soenen

Principal

CL

Charles Le Texier

Associate

LT

Lars Timmer

Principal

Christophe Van Vaeck

Associate

Bram Vanparys

Partner

Eric de La Vigne

Principal

MV

Michaël Vlemmix

Principal

Tom Voorde

Managing Partner

NW

Niklas Windmann

Associate

Boris Wirtz

Partner

203 past transactions

Equipe Zorgbedrijven

Private Equity Round in 2015
Equipe Zorgbedrijven Holding B.V. operates clinics for specialized surgery in the Netherlands. The company is headquartered in Eindhoven, the Netherlands.

Prosensa

Series B in 2008
Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics. During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology. Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.

Multiplicom N.V.

Venture Round in 2011
Multiplicom is a Belgian start-up that focuses on molecular diagnostics.

Fovea Pharmaceuticals

Series B in 2007
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.

Teads S.A.

Private Equity Round in 2011
Teads, founded in 2011, is the inventor of outstream video advertising and the leading native video advertising marketplace. Publishers work with Teads to create new video inventory, monetizing it through programmatic buying, their own sales force, or third parties including Teads Demand. Teads pioneers advertising experiences that respect the user, creating unprecedented levels of premium inventory which previously didn’t exist. Teads has a team of over 600 employees, 100 of which are in the innovation team, across 27 global offices. In May 2017, Teads became part of the Altice Group, a convergent global leader in telecom, content, media, entertainment and advertising.

Medi-Markt Homecare-Service

Acquisition in 2018
Medi-Markt is the specialist for medical aids and care aids.
Breath Therapeutics – a Zambon Group Company is pursuing groundbreaking therapies by unleashing the true potential of inhaled drug delivery. Their approach combines novel formulations of existing drugs with cutting-edge inhalation technology for the treatment of rare respiratory diseases with high unmet medical need. They are developing drug-device combinations designed to rapidly deliver high concentrations of drugs to the site of action in the lung. Their approach increases effective dosing in the lung while minimizing systemic exposure which could lead to new treatment solutions with enhanced efficacy and safety.

JenaValve Technology

Series C in 2014
JenaValve's device idea was conceived by Hans-Reiner Figulla, MD, and Markus Ferrari, MD, both cardiologists at the Friedrich Schiller University Clinic, Jena, Germany. In 2006 the company was founded to develop second generation transcatheter aortic valve implantation (TAVI) systems for transapical and transfemoral implantation. At a very early state, it became clear to their research and development as well as clinical teams that safety, precision and durability are key for successful treatment, and ultimately, patient well-being.

Innate Pharma

Series B in 2002
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Viabuild Group N.V.

Private Equity Round in 2008
Viabuild Group N.V. provides road, civil, and drainage construction services. Viabuild Group N.V. was formerly known as Verhaeren Kembo Groep NV and changed its name to Viabuild Group N.V. in October, 2012. The company is based in Mechelen, Belgium. Viabuild Group N.V. operates as a subsidiary of NV Verhaeren & Co.

Legallais

Private Equity Round in 2016
Legallais is a distributor of ironmongery, plumbing products and electricity products and is mainly active in the French market where it provides an exhaustive and high quality offering for craftsman, building operators and maintenance companies. Legallais is the reference in the market when it comes to service: in addition to a large product availability, customers can order in different ways (mobile, online, mail,...) and their automated logistics ensures a delivery within 24 hours.

AgroSavfe

Venture Round in 2013
Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.

Pronota

Series C in 2012
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

Plexxikon

Series B in 2004
Plexxikon, Inc. engages in the discovery and development of small molecule pharmaceuticals to treat human disease. The company's products include PLX204 for the treatment of diabetes; PLX4032 for the treatment of melanoma and colorectal cancer; and PLX5568 kinase inhibitors for the treatment of pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease. It develops a portfolio of clinical and preclinical stage programs in various therapeutic areas, including metabolic disease, such as obesity indications; oncology, such as osteolytic metastatic disease; and CNS, such as multiple sclerosis. The company’s portfolio of clinical and preclinical stage programs for other therapeutic areas include inflammation, such as systemic lupus erythematosus, inflammatory bowel disease, and osteoporosis; and cardiovascular, including hypertension and atherosclerosis.

WEMAS Absperrtechnik GmbH

Acquisition in 2017
WEMAS is market leader in Germany for integrated, certified solutions for road shut-off technology. The broad range of products mainly includes shutters, fall arrestors, lights, footplates and traffic cones. The core business is supplemented by other plastic products such as mortar baths, protective devices for the logistics sector, as well as articles for horse sport. The sales are exclusively for customers as well as for the trade. At the headquarters in Gütersloh, more than 120 employees work on the satisfaction of WEMAS customers.

NovoPolymers NV

Series A in 2009
NovoPolymers NV develops encapsulant solutions for the photovoltaic market. It offers thermoplastic encapsulant sheets for crystalline silicon based photovoltaic modules; and hydrocarbon thermoplastic elastomer materials. The company was founded in 2008 and is based in Puurs, Belgium.

Liquavista

Series D in 2010
Liquavista B.V., a display manufacturing company, develops electro-wetting displays in the Netherlands and internationally. It offers LiquavistaBright that offers a combination of brightness in natural light and bold contrast to video; LiquavistaColor, which enables eReader devices to offer bright, full color, and low power video capable displays; and LiquavistaVivid, a transflective mode display, which represents the eReader application. Its products are used in portable and mobile applications, such as phones, watches, cameras, DVD players, and automotive applications. The company was founded in 2006 and is based in Eindhoven, the Netherlands with additional offices in the Netherlands, the United Kingdom, and Hong Kong.

Well Services Group

Private Equity Round in 2014
The Well Services Group is a total well service provider for the oil and gas industry. By using well maintained 'state of the art' equipment and experienced personnel we can offer high quality services with a high efficiency. By being a flexible operating company we can respond fast to the costumers needs.

JenaValve Technology

Series C in 2013
JenaValve's device idea was conceived by Hans-Reiner Figulla, MD, and Markus Ferrari, MD, both cardiologists at the Friedrich Schiller University Clinic, Jena, Germany. In 2006 the company was founded to develop second generation transcatheter aortic valve implantation (TAVI) systems for transapical and transfemoral implantation. At a very early state, it became clear to their research and development as well as clinical teams that safety, precision and durability are key for successful treatment, and ultimately, patient well-being.

Prosonix Ltd.

Series B in 2012
Prosonix Ltd. operates as a specialty pharmaceutical company, which develops and markets a portfolio of inhaled respiratory medicines to treat asthma and chronic obstructive pulmonary diseases. It develops generic mono and combination therapies based on inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA); and dual and triple combination therapies for respiratory diseases based on its multiple-component particle technology. The company was founded in 2006 and is based in Oxford, United Kingdom. As of June 15, 2015, Prosonix Ltd. operates as a subsidiary of Circassia Limited.

Arrow Therapeutics

Series B in 2003
Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

Verkley

Acquisition in 2021
Verkley specialises in building and maintaining underground cable and pipeline networks for energy and water.

Clear2Pay

Series D in 2006
Clear2Pay is an innovative payments technology company focused on delivering globally applicable solutions for secure, timely and streamlined payments processing. Clear2Pay's Open Payment Framework (OPF) enables financial institutions to improve internal payments processing efficiencies whilst at the same time providing their clients with better payment services that are faster, with richer payments related information. Clear2Pay's solutions within the Service- Oriented Architecture (SOA) based Open Payment Framework offer financial institutions the ability to process payments through a centralised payments engine that utilises a library of re-useable business services across all payment types. The bank can thus combine new services models with existing infrastructures, thereby protecting previous investments whilst gradually moving to a more modern efficient payments environment.

NovoPolymers NV

Private Equity Round in 2013
NovoPolymers NV develops encapsulant solutions for the photovoltaic market. It offers thermoplastic encapsulant sheets for crystalline silicon based photovoltaic modules; and hydrocarbon thermoplastic elastomer materials. The company was founded in 2008 and is based in Puurs, Belgium.

Nomadesk NV

Series B in 2010
Nomadesk is a European SaaS company, founded in 2004 and focused on Business File Sharing & Synchronization technology.  We are leading developers of cloud software for sharing and synchronizing digital documents, allowing foremost business users to edit, share, synchronize and secure files from anywhere – online and offline! Our company maintains datacenter facilities in Europe (Frankfurt, Amsterdam) and USA (Asheville – NC) for our European and American customers, respectively. ​ Nomadesk mainly targets resellers, service providers and system integrators, who offer the Nomadesk solutions to their clients – usually under a proprietary name, or brand. ​ Nomadesk is part of UnifiedPost, an international BPaaS provider of integrated business process optimisation solutions including complete document delivery and processing solutions, complemented by payment, financial supply chain, credit management and secure e-identity solutions.

Itineris

Venture Round in 2015
Founded in 2003, Itineris is a global technology company focused on delivering IT solutions and services that drive greater operational value and strengthen customer care capabilities for utility organizations in the power, gas and water markets. A Microsoft Gold Partner for ERP, Itineris is the developer of UMAX®, a customer information system (CIS) fully integrated with, and leveraging the power of, Microsoft’s cutting-edge ERP platform, Dynamics AX. For more information, please go to: www.itineris.net

Psytechnics

Venture Round in 2006
Psytechnics is a leading authority for voice and video service management. The company offers a range of active and passive software solutions for both Enterprises and Service Providers markets. These software solutions are used to demonstrably improve the performance of real-time communications, including the most advanced unified communications applications and networks designs. Psytechnics' software is specially calibrated for voice, video (from softclient to Telepresence), and fixed-mobile services. The company's core product, Experience Manager, is the first IT service management solution that monitors, alarms, diagnoses and reports on services based on users QoE (Quality of Experience). The software is prized as highly accurate and intuitive, and supports communications platforms from any vendor, including Cisco, Avaya, Nortel, Genband, Polycom, Tandberg, Radvision, Acme Packet, IBM Sametime, Microsoft, and others.

Movea

Venture Round in 2008
Movea is a provider of motion sensing and data fusion software, firmware, and IP for the consumer electronics, particularly smart phones and tablets, sports and fitness and eHealth industries. Movea's proprietary SmartMotion™ technology - unique motion processing capabilities - enable customers and partners to quickly add motion intelligence to their products, providing reduced risk, cost, and time-to-market advantages for delivering compelling new motion-based features that create more value and a more exciting user experience for the consumer. Movea has a global presence with headquarters in Grenoble, France, a U.S. subsidiary in Silicon Valley, California, as well as technology and manufacturing partners and distributors around the world. The company was recently named a “Cool Vendor for 2012” by leading analyst firm Gartner Inc. Movea, Inc. was formerly known as Gyration, Inc. and changed its name to Movea, Inc. in January 2008. The company was founded in 1989 and is based in Milpitas, California. As of December 21, 2007, Movea, Inc. operates as a subsidiary of Movea SA.

Private Outlet SAS

Venture Round in 2010
Private Outlet SAS engages in the online retail of apparel for men, women, and children in France, Germany, Austria, Belgium, Spain, Ireland, Italy, Luxembourg, the Netherlands, Portugal, and the United Kingdom. It offers ready to wear clothing, footwear, accessories, fashion products, decoration products, jewelry, high-tech products, appliances, sports products, beauty products, house products, and lingerie for its members. The company was founded in 2006 and is based in Saint-Denis, France. Private Outlet SAS operates as a subsidiary of Andrino.

Movetis

Series A in 2007
Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.

CoWare

Series D in 2002
Software and consulting services to ip, semiconductor and electronics companies

Innate Pharma

Series A in 2000
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Luciad

Acquisition in 2013
Luciad provides high performance software tools for rapid application development of advanced systems. Our applications simplify the lives of developers and end users with advanced visual analytics that allow them to unlock the potential of real time location intelligence and create the foundations for next generation geospatial systems. From safeguarding critical assets to creating the digital infrastructure for smart cities, we help users implement intuitive command and control systems. Our customers depend on Luciad for high performance visualization that allows them to implement scalable solutions.

Elixent

Series B in 2003
Elixent, Ltd. supplies reconfigurable arithmetic processors in the United Kingdom. It offers reconfigurable semiconductor intellectual property, a technology that enables user to change the function of a chip even when in use. The company also offers silicon devices and supporting software. In addition, the company provides D-Fabrix, a reconfigurable algorithm processing technology that provides application specific integrated circuit designers with an alternative to fixed function chips; and reprogrammable algorithm solutions for system on chip platforms. Elixent, Ltd. is a spin off of Hewlett-Packard's Bristol Research Laboratories. The company was founded in October 2000 and is based in Bristol, the United Kingdom.

Topas Therapeutics GmbH

Series B in 2020
Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

United Dutch Breweries

Acquisition in 2015
United Dutch Breweries B.V. produces and supplies beer. The company provides lagers, non-alcoholic malt beverages, dark malt beverages, ciders, and fruit beers. It offers products through on-and off-trade distributors, and retailers worldwide. The company was founded in 1968 and is based in Breda, the Netherlands. United Dutch Breweries B.V. is a former subsidiary of Anheuser-Busch InBev SA/NV.

Onedirect Comunicaciones

Acquisition in 2010
Since 1999, Onedirect has continued to grow and expand throughout Europe established first in France and then in Spain, the company also introduced in Italy, Portugal and Germany. With an available stock of over 2000 references of products and accessories, over 96% of orders are shipped the same day!

Almaviva Santé

Private Equity Round in 2013
Almaviva Santé owns and operates hospitals and health care clinics. The company was founded in 2007 and is headquartered in Marseille, France.

FIRE1

Series C in 2018
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

GRUPA DataContact Sp z o.o.

Venture Round in 2010
DataContact, a Warsaw, Poland-based provider of outsourced contact center services. Founded in 1995, DataContact was subsidiary of Axel Springer AG under the name of Axel Springer Kontakt between 2001 and 2010. The group currently operates 185 workstations in two locations and focuses on customer service, marketing and sales activities for the Polish and German markets. It offers both inbound and outbound call services as well as non-voice services. Customers include tier-1 clients from multiple industries, including publishing, IT, financial services and transportation.

Xanthus Pharmaceuticals

Series B in 2006
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.

Spineart Geneva SA

Venture Round in 2016
Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients. Spineart is a pioneer in its field, having introduced unique patented and clinically validated technologies in the fields of Minimally Invasive Surgery, Motion Preservation, Fusion, Biologics, and Fractures Treatment. Spineart markets a complete portfolio combining traceable barcoded sterile packed implants with compact instrument sets, thus proudly promoting greater safety, cost-efficiency, and compliance at the hospital.

Diatos

Series D in 2007
Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).

Ceres

Series F in 2007
Ceres is a non-profit organization that advocates for sustainability leadership. The organization mobilizes a network of investors, companies, and public interest groups to accelerate and expand the adoption of sustainable business practices and solutions to build a healthy economy. It also carries out research in business sustainability trends as well as insurance and banking sector responses to climate change, electric utilities emissions, fuel economy standards, and climate risk disclosure. Ceres is headquartered in Boston, Massachusetts.

Complix

Series B in 2013
Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that are difficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.

Movea

Venture Round in 2012
Movea is a provider of motion sensing and data fusion software, firmware, and IP for the consumer electronics, particularly smart phones and tablets, sports and fitness and eHealth industries. Movea's proprietary SmartMotion™ technology - unique motion processing capabilities - enable customers and partners to quickly add motion intelligence to their products, providing reduced risk, cost, and time-to-market advantages for delivering compelling new motion-based features that create more value and a more exciting user experience for the consumer. Movea has a global presence with headquarters in Grenoble, France, a U.S. subsidiary in Silicon Valley, California, as well as technology and manufacturing partners and distributors around the world. The company was recently named a “Cool Vendor for 2012” by leading analyst firm Gartner Inc. Movea, Inc. was formerly known as Gyration, Inc. and changed its name to Movea, Inc. in January 2008. The company was founded in 1989 and is based in Milpitas, California. As of December 21, 2007, Movea, Inc. operates as a subsidiary of Movea SA.

Arrow Therapeutics

Venture Round in 2002
Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

La Comtoise

Acquisition in 2018
La Comtoise develops and supplies tailor-made cheese solutions to industrial food processing groups.

GTX medical

Venture Round in 2021
GTX Medical is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Innate Pharma

Series C in 2004
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Liquavista

Series B in 2008
Liquavista B.V., a display manufacturing company, develops electro-wetting displays in the Netherlands and internationally. It offers LiquavistaBright that offers a combination of brightness in natural light and bold contrast to video; LiquavistaColor, which enables eReader devices to offer bright, full color, and low power video capable displays; and LiquavistaVivid, a transflective mode display, which represents the eReader application. Its products are used in portable and mobile applications, such as phones, watches, cameras, DVD players, and automotive applications. The company was founded in 2006 and is based in Eindhoven, the Netherlands with additional offices in the Netherlands, the United Kingdom, and Hong Kong.
Riaktr is a Belgian scale-up founded in 2009 and backed by first class investors (Fortino, Endeit, GIMV). We started as a service company under the name ‘Real Impact Analytics’. At the time, Big Data was the new big thing, driving important corporate investments. Yet, too often such investments were not yielding the desired returns. Since day one, we pursue a clear mission: leverage the value of telecom data. We do this by starting from the field to build user-centric frameworks driving results. We resist the ‘black box’ principle by putting data at the service of human intelligence and bringing teams together under a collaborative approach. Our brand Riaktr, adopted in 2018, symbolizes our pivot from a services business to a product company. Today our software products address two major questions faced by telcos: - How can I optimize my network CAPEX investments? - How can I optimize my Sales & Distribution operations? Behind the scenes, we are a team of computer scientists, engineers and business consultants based in the heart of Brussels, with a local presence close to our clients in South-Africa and Brazil. We have worked in many countries in Africa, Latin America, the Caribbean and Europe. We work with six of the ten biggest telecom groups to revolutionize the telecom and Consumer Goods industries.

Ambit Biosciences

Series D in 2011
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

ImmunOs Therapeutics

Series B in 2022
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

GOVECS

Venture Round in 2012
GOVECS was founded in 2009 with the objective to provide clean, efficient, reliable and affordable transportation on the leading edge of technology for electrical mobility. Top engineers and designers are working on the development of electric vehicles that combine style and True Electric Mobility.

ChemoCentryx, Inc.

Series C in 2006
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Camel-IDS

Series B in 2022
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

McPhy

Venture Round in 2010
McPhy Energy S.A. develops and supplies hydrogen production, storage, and distribution equipment for hydrogen energy, zero emission mobility, and industrial hydrogen markets worldwide. The company offers alkaline electrolyzers, including small, medium, and large hydrogen production units; and hydrogen storage solutions. It also designs medium and large hydrogen stations; and integrated hydrogen solutions. The company was founded in 2008 and is based in La Motte, France.

CoWare

Series E in 2003
Software and consulting services to ip, semiconductor and electronics companies

CoWare

Series B in 1999
Software and consulting services to ip, semiconductor and electronics companies

Eurocept

Private Equity Round in 2013
Eurocept, an Ankeveen, the Netherlands-based healthcare company. Founded in 2001 by CEO Mike van Woensel, Eurocept sells specialized medicines and provides medical homecare services. Eurocept Pharmaceuticals is responsible for the registration, marketing, distribution and sale of speciality medicines in the fields of anesthetics, psychiatry, urology, pediatrics and infectious diseases. Eurocept Homecare provides medical specialist homecare and related out-patient medical technology for medicine and food administration.

Proficient Systems

Series B in 2002
Proficient Systems is a leading enterprise software company that develops solutions enabling companies to increase revenue and sales productivity. By identifying and connecting online sales opportunities with offline sales and service operations Proficient enables companies to successfully drive new customer acquisition, lead generation and an improved online customer experience. Headquartered in Atlanta, Georgia, Proficient was founded by successful entrepreneur, Gregg Freishtat. Gregg recognized that large enterprises selling complex, consultative products and services, like mortgages or insurance, had made significant investments in their e-business and in their sales and service organizations - but for some reason the two weren't connected. His belief was that if the two were connected, the enterprises would see a significant increase in revenue while delivering superior customer service and a better customer online experience. With this belief in mind, he assembled a group of professionals with decades of experience creating and delivering solutions to large enterprises, to create a strategic business solution to meet these objectives. In October 2000, Proficient was born. Today, organizations are benefiting from Gregg's vision and his ability to create a company to make his vision become a reality.

Laser 2000 GmbH

Acquisition in 2018
Laser 2000 is an independent European suppliers of innovative laser and photonics solutions. The company's comprehensive range of products extends from lasers and light sources for the processing of materials, over measurement equipment and fibre optics to 3D imaging, optical power and energy meters as well as cameras. With more than 30 years of experience in the market, Laser 2000 is a photonics pioneer and can therefore benefit from long-standing customer and supplier relationships. It serves renowned companies and research institutes in the fields of automation and sensor technology, optical communications and network technologies, biotech and medicine, automotive and aerospace.

Inside Secure

Series A in 2005
Mobile security and secure transaction offerings to protect critical assets including connected devices, content, services and transactions.

VirtenSys

Series B in 2008
VirtenSys was formed in 2005 to address a key problem in the IT industry. The IT industry today is caught between a 'rock and a hard place'. On one side IT budgets are severely constrained with analysts predicting single figure percentage growth for the foreseeable future. IT providers are expected to deliver increased value both in terms of reduced asset cost and 'Total Cost of Ownership'. This TCO factor is becoming dominated by issues like floor space, power consumption, thermal management and system maintenance costs. At the same time the workload on IT systems is increasing much faster than the budgets. More importantly however, the dynamics of the workload are also changing. Successful companies need to be more agile in responding to changing business conditions and need an IT infrastructure which can adapt equally fast. New business models are also emerging with analysts predicting that by 2010, 25% of all IT services will be supplied through utility computing models, requiring even more dynamic workload capabilities. To add to this challenge, the size of the industry, particularly with respect to the investment in software and systems, demands an evolutionary forward migration path. The industry does not tolerate 'fork lift' upgrades.

AgroSavfe

Series C in 2019
Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.

Ambit Biosciences

Series D in 2007
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

JenaValve Technology

Series C in 2015
JenaValve's device idea was conceived by Hans-Reiner Figulla, MD, and Markus Ferrari, MD, both cardiologists at the Friedrich Schiller University Clinic, Jena, Germany. In 2006 the company was founded to develop second generation transcatheter aortic valve implantation (TAVI) systems for transapical and transfemoral implantation. At a very early state, it became clear to their research and development as well as clinical teams that safety, precision and durability are key for successful treatment, and ultimately, patient well-being.

MVZ Holding

Acquisition in 2017
MVZ Holding focusses on providing best in class primary medical care and has grown successfully by executing a disciplined expansion strategy. The company currently runs more than 25 medical practices in different regions in Switzerland and plans further expansion within the country.

ActoGeniX

Venture Round in 2007
ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.

Hypnion

Series A in 2000
Hypnion is a neuroscience drug discovery and development company that develops novel therapeutics for the treatment of central nervous system disorders. The company develops treatments for sleep- and wake-alertness disorders and circadian rhythm abnormalities. Hypnion offers SCORE-2004, a drug discovery platform that is able to measure drugs’ impact on sleep and wake parameters. Hypnion is acquired by Eli Lilly and Company. Hypnion was founded in 2000 and is based in Worcester, Massachusetts.

Cegeka NV

Venture Round in 2017
Cegeka’s mission is to help customers survive and thrive in a world where the rules of the game are constantly changing. Cegeka is an independent European IT services provider. The company helps its customers with IT consultancy projects, the integration of ICT infrastructure, the development and implementation of applications and outsourcing. The ICT company, originally Belgian, houses the ICT of its customers in its own data centres in Hasselt, Leuven and Veenendaal (the Netherlands). A new, state-of-the-art data centre is opening in the Dutch city of Geleen at the end of 2015. Cegeka Group has over 3500 employees, and is expecting a consolidated turnover of €400m in 2015. Cegeka has branches in Belgium, Germany, France, Italy, the Netherlands, Luxembourg, Austria, Poland, Romania, Slovakia and the Czech Republic.

Wolf Group

Acquisition in 2014
Wolf Group designs, manufactures and distributes women’s Lingerie, mostly under its own brands: Rosy (www.rosy.fr), Sans-Complexe (www.sanscomplexe.com), Billet Doux (www.billetdoux.com), Oups (www.oups-lingerie.com) and Jardin Secret. In addition, it also designs and manufactures collections for major retailers and prestigious international brands

AGY Therapeutics

Series C in 2004
AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specific pathways underlying central nervous system diseases. By harnessing these capabilities, AGY identified potential target proteins that can be modulated to block the progression of the disease process. This is paving the way for novel CNS therapeutics and future growth for AGY.

Pronota

Series A in 2006
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

ChemoCentryx, Inc.

Series D in 2007
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Ablynx

Series C in 2006
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Easyvoyage

Private Equity Round in 2009
Easy Voyage is a travel website where users can book flights, hotels and car rentals.

VirtenSys

Series A in 2006
VirtenSys was formed in 2005 to address a key problem in the IT industry. The IT industry today is caught between a 'rock and a hard place'. On one side IT budgets are severely constrained with analysts predicting single figure percentage growth for the foreseeable future. IT providers are expected to deliver increased value both in terms of reduced asset cost and 'Total Cost of Ownership'. This TCO factor is becoming dominated by issues like floor space, power consumption, thermal management and system maintenance costs. At the same time the workload on IT systems is increasing much faster than the budgets. More importantly however, the dynamics of the workload are also changing. Successful companies need to be more agile in responding to changing business conditions and need an IT infrastructure which can adapt equally fast. New business models are also emerging with analysts predicting that by 2010, 25% of all IT services will be supplied through utility computing models, requiring even more dynamic workload capabilities. To add to this challenge, the size of the industry, particularly with respect to the investment in software and systems, demands an evolutionary forward migration path. The industry does not tolerate 'fork lift' upgrades.

Nereus Pharmaceuticals

Series D in 2005
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

Openbravo SL

Series B in 2008
Openbravo is a world leader in the commercial open source software space helping midsize and large specialty retailers around the globe successfully manage continuous business change and innovation in today's fast-changing retail industry. Openbravo offers the Openbravo Commerce Suite, a multichannel retail business solution that allows specialty retailers to manage their entire business and transform their physical store channel to deliver great shopping experiences, while enabling more focus on business differentiation thanks to a highly flexible and extendible commerce technology platform, which is mobile-enabled and cloud-ready. Openbravo has offices in France, India, Mexico and Spain and distributes its software solutions through a global network of Authorized Partners.

CoScale

Venture Round in 2015
CoScale NV provides software solutions for IT operations analytics. It offers integrated platform to monitor full stack of containerized applications. It also provides COSCALE Application Performance Analyzer software that gathers and correlates data from Web applications and the underlying infrastructure to automatically identify and isolate disruptions, inefficiencies, and failures in Web applications; and enable organizations to optimize its infrastructure. The company offers its product as a subscription and licensing model for organizations operating in areas, such as e-commerce, online banking, online customer service, etc. CoScale NV was founded in 2013 and is based in Ghent, Belgium.

JenaValve Technology

Venture Round in 2020
JenaValve's device idea was conceived by Hans-Reiner Figulla, MD, and Markus Ferrari, MD, both cardiologists at the Friedrich Schiller University Clinic, Jena, Germany. In 2006 the company was founded to develop second generation transcatheter aortic valve implantation (TAVI) systems for transapical and transfemoral implantation. At a very early state, it became clear to their research and development as well as clinical teams that safety, precision and durability are key for successful treatment, and ultimately, patient well-being.

Itineris

Venture Round in 2017
Founded in 2003, Itineris is a global technology company focused on delivering IT solutions and services that drive greater operational value and strengthen customer care capabilities for utility organizations in the power, gas and water markets. A Microsoft Gold Partner for ERP, Itineris is the developer of UMAX®, a customer information system (CIS) fully integrated with, and leveraging the power of, Microsoft’s cutting-edge ERP platform, Dynamics AX. For more information, please go to: www.itineris.net

Transdev

Private Equity Round in 2013
With its complementary geographic footprint, expertise and service offerings, Transdev offers a unique response to public transport needs. Transdev keeps operations and decision-making local and close to the client, backed up with consistent, high-quality standards that leverage the company's international expertise, best practices and resources in order to deliver industry-leading results. Transdev, an incorporated company with its own Board of Directors, is supported by its two major shareholders, Caisse des Depôts and Veolia Environnement. Listening to customers, anticipating and responding to their needs and expectations, constantly seeking ways to provide simpler, more accessible and more personalized service. Transdev strives to make each trip a unique experience, with passion and commitment.

Inside Secure

Series B in 2007
Mobile security and secure transaction offerings to protect critical assets including connected devices, content, services and transactions.

CoreOptics

Venture Round in 2008
CoreOptics is the leading providers of 10G and 40G Distortion Tolerant Transponder Modules and IC solutions for Metro, Regional and Long Haul optical & data networking markets.With a belief that optical communications networks must become open systems that economically transmit information regardless of data rate or fiber types, CoreOptics provides the only field-proven MLSE-based equalization solutions on the market today. This innovative technology helps Tier 1 systems vendors and carriers deploy the next generation of high-performance networks using their existing fiber infrastructure. CoreOptics' 10G and 40G Distortion Tolerant Transponder Modules eliminate the need for Optical Compensators and the respective Second Stage Amplifiers, allowing customers to reduce their first-in deployment cost by up to 30%.

ARS Traffic & Transport Technology

Private Equity Round in 2012
ARS Traffic & Transport Technology has been providing traffic and transport technology solutions to businesses and government bodies since 1997. It is active in its home market of the Netherlands, but also internationally. The intelligent transport system market is always on the move, in every sense of the word. A dynamic market like this demands a specialised partner, able to cost-effectively integrate state-of-the-art, client-specific technology with existing systems, but also able to develop new hi-tech concepts.

Vandemoortele NV

Private Equity Round in 2009
Vandemoortele is a family-owned Belgian foods group with a European dimension. It manufactures and sells high-quality food products in two segments: frozen bakery products (Bakery Products) and margarines and fats (Lipids).

AgroSavfe

Series B in 2017
Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.

Impact

Acquisition in 2018
Impact is a temporary employment agency for specialists in technics, construction and office work. IMPACT is a specialized temporary employment agency with its headquarters in Hasselt. Their main objective? By means of a personal approach, a clear focus, and a great deal of engagement and expertise, they aim to match employers with specialists who are looking for a job in the fields of technics, construction, or office work. Thus, they contribute to the successful growth of enterprises and to the professional satisfaction of the experts who found a job thanks to them.

Xanthus Pharmaceuticals

Series B in 2003
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.

Bioconnection B.V.

Secondary Market in 2022
Bioconnection B.V. provides biopharmaceutical development and manufacturing services for small and medium-sized biopharmaceutical companies. It acts as an interface for expertise that is needed to complete clinical trials and production to good manufacturing practices (GMP) standards, as well as offers access to GMP manufacturing facilities. The company offers clinical fill and finish services for product, including liquid fill or lyophilization intended for vials. It also provides access to a range of development services, including formulation development and manufacturing of active biopharmaceutical ingredients, process development and scale-up of biopharmaceutical products, pre-clinical and early clinical development, stability studies, support clinical trials, and commercial activities. The company was founded in 2005 and is based in Oss, the Netherlands. BioConnection B.V. operates as a subsidiary of Merck & Co., Inc.

Gemidis

Series C in 2006
Gemidis is a spin-off company from Ghent University (Belgium) and IMEC (Belgium) and was officially founded in August 2004. Gemidis develops, produces and sells LCOS imagers and driver electronics for both consumer and professional markets.

Anjarium Biosciences AG

Series A in 2021
Anjarium Biosciences is a transforming exosomes from cellular message couriers to potent therapeutic carriers for debilitating diseases. By harnessing the delivery propensity of our body’s natural communication network, we are forward engineering evolution to build a product engine for a new generation of targeted nanomedicines. Anjarium’s Hybridosome® platform creates unmatched advantages in the realm of engineering exosomes to address the therapeutic areas of cancer and rare genetic diseases.

Luma International

Series A in 2009
Luma International was established in 2009 by a team of innovators, entrepreneurs and leading professionals in digital and personalized marketing. A successful mixture of knowledge and expertise. No matter how diverse the backgrounds of the founders and investors, they shared the same passion: innovation, with intelligent and effective communication as the objective. That objective took shape in Luma, an on-demand marketing platform for field and channel sales. It enables medium and large companies such as Toyota, Mercedes-Benz, Coca-Cola, Bacardi, P&V and others to create personalized marketing materials on-demand, which helps save money and drive sales. Using this solution, companies offer their sales and marketing organizations better support, enhance their marketing flexibility and improve the effectiveness of their campaigns, while still guaranteeing brand consistency. With Luma, marketing capitalizes fully on the sales organization's objectives. Because the needs to which Luma answers are not market or sector-related, companies from a variety of sectors have already implemented Luma successfully. Not only does Luma score well among users, but the platform has also garnered prestigious nominations and awards. The Luma platform’s capabilities reflect attributes of Marketing Resource Management, Enterprise 2.0 and Ecommerce 2.0. As the company continues to develop new capabilities, it pushes its technology further into these three areas. Today, Luma International has offices in Antwerp (Belgium), Rotterdam (The Netherlands), Paris (France) and Redwood Shores, CA (USA). For more information visit www.lumacentral.com.
PamGene has a unique proprietary array-based platform to measure the activities of kinases & nuclear receptors, enabling deeper understanding of drug interactions with these important classes of signalling molecules. PamGene's patented technology finds a wide range of applications including lead identification and optimization, (pre) clinical translational research and biomarker development.

Topas Therapeutics GmbH

Series A in 2016
Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

ImCheck Therapeutics SAS

Series C in 2022
ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

GreenPeak Technologies BV

Venture Round in 2006
GreenPeak Technologies BV, a fabless semiconductor/system company, develops ultra-low power wireless data communication controller chips for smart home applications and consumer electronics. It provides communication controller semiconductor products and software technologies for smart home data communications; a range of IEEE 802.15.4 and ZigBee silicon solutions; and Senior Lifestyle sensor and cloud based intelligent system technology to enable children and their elderly parents to privately and securely share lifestyle information. The company also offers integration, support, and training services. It markets and sells its products to OEMs and ODMs in the United States, Europe, Asia, and Latin-America. GreenPeak Technologies BV has a strategic partnership with Sensara. GreenPeak Technologies BV was formerly known as Xanadu Wireless BV and changed its name to GreenPeak Technologies BV in 2007. The company was founded in 2004 and is based in Utrecht, the Netherlands with additional offices in Belgium, China, France, the United States, Japan, and Korea. As of April 29, 2016, GreenPeak Technologies BV operates as a subsidiary of Qorvo, Inc.

Topas Therapeutics GmbH

Series B in 2021
Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

France Thermes Holding SAS

Acquisition in 2018
The group France Thermes is the organizing body of all operating subsidiaries, which include: The Thermal Resorts of Bagnoles de l'Orne (Normandy) and Châtel-Guyon (Auvergne) since January 1, 2017. The group is founded on a multi-expertise in the thermal environment, around three main skills:

MEGA International S.A.

Private Equity Round in 2016
MEGA International S.A., a software development company, develops and markets a range of software solutions to manage enterprise complexity for Fortune 500 companies, SMEs, and government agencies globally. It offers HOPEX, an integrated software solution for business process analysis, IT portfolio management, governance, risk and compliance, and platform and shared services. The company also provides HOPEX Cloud, an integrated cloud platform for software solutions to help drive business and IT transformation. In addition, it offers EAMS assessment, design, implementation, support, and training services. The company serves banking and insurance, defense and security, energy and manufacturing, government, pharma, food and chemical, retail, and telecoms and services customers. It serves its customers through a network of distributors worldwide. The company was founded in 1991 and is based in Paris, France with additional offices in the United States, Italy, Germany, the United Kingdom, México, Singapore, Morocco, and Australia.

ActoGeniX

Private Equity Round in 2009
ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.

iSTAR Medical

Series C in 2019
iSTAR Medical SA was created in 2010 as a spinout of Healionics Corporation with support from Belgium's Region Wallonne government. In 2011, iSTAR expanded to its new eco-friendly R&D and Manufacturing facility in CREALYS Scientific Park near Namur, Belgium. By 2012, iSTAR received ISO 13485 and ISO 9001 Quality Systems Certifications and achieved CE Mark approval of its first device - STARflo™ Glaucoma Implant.

JenaValve Technology

Series B in 2010
JenaValve's device idea was conceived by Hans-Reiner Figulla, MD, and Markus Ferrari, MD, both cardiologists at the Friedrich Schiller University Clinic, Jena, Germany. In 2006 the company was founded to develop second generation transcatheter aortic valve implantation (TAVI) systems for transapical and transfemoral implantation. At a very early state, it became clear to their research and development as well as clinical teams that safety, precision and durability are key for successful treatment, and ultimately, patient well-being.

Hypnion

Series B in 2003
Hypnion is a neuroscience drug discovery and development company that develops novel therapeutics for the treatment of central nervous system disorders. The company develops treatments for sleep- and wake-alertness disorders and circadian rhythm abnormalities. Hypnion offers SCORE-2004, a drug discovery platform that is able to measure drugs’ impact on sleep and wake parameters. Hypnion is acquired by Eli Lilly and Company. Hypnion was founded in 2000 and is based in Worcester, Massachusetts.

Hypnion

Series B in 2005
Hypnion is a neuroscience drug discovery and development company that develops novel therapeutics for the treatment of central nervous system disorders. The company develops treatments for sleep- and wake-alertness disorders and circadian rhythm abnormalities. Hypnion offers SCORE-2004, a drug discovery platform that is able to measure drugs’ impact on sleep and wake parameters. Hypnion is acquired by Eli Lilly and Company. Hypnion was founded in 2000 and is based in Worcester, Massachusetts.

Liquavista

Series A in 2006
Liquavista B.V., a display manufacturing company, develops electro-wetting displays in the Netherlands and internationally. It offers LiquavistaBright that offers a combination of brightness in natural light and bold contrast to video; LiquavistaColor, which enables eReader devices to offer bright, full color, and low power video capable displays; and LiquavistaVivid, a transflective mode display, which represents the eReader application. Its products are used in portable and mobile applications, such as phones, watches, cameras, DVD players, and automotive applications. The company was founded in 2006 and is based in Eindhoven, the Netherlands with additional offices in the Netherlands, the United Kingdom, and Hong Kong.

sofatutor GmbH

Venture Round in 2021
sofatutor GmbH, an edtech company, owns and operates an online learning platform for K-12 pupils and students in Europe. It offers sofatutor.com, an online platform that provides video lessons, practice problems, worksheets, and homework chat for students. The company’s website provides courses and videos in German, mathematics, primary school, English, physics, chemistry, biology, and other subjects. It serves students, teachers, and parents in Germany and internationally. sofatutor GmbH was founded in 2008 and is based in Berlin, Germany.

Interwise

Series C in 2001
Interwise provides voice, Web, and video conferencing solutions for the enterprise. The company offers AT&T Connect, an IP software, which is used for voice conferences, Web meetings, virtual training, Web seminars, Webcasts, broadcasts, and recordings. It serves technology, manufacturing, pharmaceutical, insurance, automotive, and retail industries. The company was founded in 1994 and is headquartered in Cambridge, Massachusetts with additional offices in Israel, Japan, the United Kingdom, Switzerland, France, and Germany.

Arplas Systems

Private Equity Round in 2016
Arplas Europe BV engages in the development, application, and marketing of various welding-applications for the production of passenger cars worldwide. The company was founded in 1971 and is based in Amersfoort, the Netherlands with manufacturing, service, and training facilities in Europe, North America, and Korea; and service representatives in China and Brazil. It also has locations in Europe and Africa. Arplas Europe BV operates as a subsidiary of AL-S Technology B.V.

Prosensa

Venture Round in 2012
Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics. During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology. Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.

NovoPolymers NV

Venture Round in 2012
NovoPolymers NV develops encapsulant solutions for the photovoltaic market. It offers thermoplastic encapsulant sheets for crystalline silicon based photovoltaic modules; and hydrocarbon thermoplastic elastomer materials. The company was founded in 2008 and is based in Puurs, Belgium.

Itho Daalderop

Acquisition in 2016
Itho Daalderop Group B.V. manufactures and markets HVAC products for residential sector. The company’s products include central heating systems, heat pumps, solar boilers, kitchen boilers, and ventilation systems. Itho Daalderop Group B.V. was founded in 1880 and is based in Tiel, the Netherlands. The company operates as a subsidiary of Klimaatgarant B.V.

Thinkstep AG

Series B in 2014
Thinkstep enables organizations worldwide to succeed sustainably. Their industry-leading software, data and services drive operational excellence, product innovation, brand value and regulatory compliance. With a global presence in 19 countries they serve more than 2,000 companies, including 40 percent of the Fortune 500 such as BASF, Hewlett-Packard, Interface, Siemens, Unilever and Volkswagen.

Fovea Pharmaceuticals

Series A in 2005
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.

TorreyPines Therapeutics

Series C in 2005
TorreyPines Therapeutics engages in the discovery and development of small molecule compounds in the United States. Its product portfolio includes both candidates from its drug targeting platforms and in-licensed and acquired product candidates. As of August 31, 2010, its pipeline includes three clinical development programs. It also has three other clinical-stage product candidates, for which it is seeking business development partners, and it has four preclinical product candidates it is developing, three of which are based upon its drug-targeting platforms.

One of A Kind Technologies B.V.

Venture Round in 2018
One of A Kind Technologies B.V. is a holding company. The company, through its subsidiaries, develops camera inspection technology, vision solutions, and industrial automation products. The company is headquartered in Eindhoven, the Netherlands.

ImCheck Therapeutics SAS

Series B in 2019
ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

TrustTeam

Private Equity Round in 2011
Trustteam NV provides information technology solutions to businesses. It offers cloud, security, telephony (VoIP), software, hardware, audit, support, and other services. The company was founded in 2002 and is based in Kortrijk, Belgium with branch locations in Heusden-Zolder, Belgium; and Paris, France.

Alro group

Acquisition in 2019
The Alro Group is a specialises in coating of plastic and metal parts for the automotive sector. Alro Group grown from a small coating company to a large reputed group with several branches in Western and Central Europe, specialized in coating of plastic and metal parts for the automotive sector.

Santhera Pharmaceuticals

Series B in 2005
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy.

Psytechnics

Series C in 2004
Psytechnics is a leading authority for voice and video service management. The company offers a range of active and passive software solutions for both Enterprises and Service Providers markets. These software solutions are used to demonstrably improve the performance of real-time communications, including the most advanced unified communications applications and networks designs. Psytechnics' software is specially calibrated for voice, video (from softclient to Telepresence), and fixed-mobile services. The company's core product, Experience Manager, is the first IT service management solution that monitors, alarms, diagnoses and reports on services based on users QoE (Quality of Experience). The software is prized as highly accurate and intuitive, and supports communications platforms from any vendor, including Cisco, Avaya, Nortel, Genband, Polycom, Tandberg, Radvision, Acme Packet, IBM Sametime, Microsoft, and others.

CoWare

Series F in 2007
Software and consulting services to ip, semiconductor and electronics companies

Covagen

Series B in 2013
Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen’s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.

CareX SA

Series B in 2004
CareX SA is a biopharmaceutical company that develops novel treatments for metabolic and immune system disorders which includes diabetes and obesity. The company focuses on metabolic syndrome, a cluster of inter-related disorders of the body’s metabolism, including high blood pressure, high insulin levels, excess body weight, and abnormal cholesterol levels, that exposes individuals to the development of type 2 diabetes, heart diseases, and strokes. CareX SA is a France-based company that was founded in 2001 and the company was acquired by 7TM Pharma on May 24, 2006.

CoreOptics

Venture Round in 2006
CoreOptics is the leading providers of 10G and 40G Distortion Tolerant Transponder Modules and IC solutions for Metro, Regional and Long Haul optical & data networking markets.With a belief that optical communications networks must become open systems that economically transmit information regardless of data rate or fiber types, CoreOptics provides the only field-proven MLSE-based equalization solutions on the market today. This innovative technology helps Tier 1 systems vendors and carriers deploy the next generation of high-performance networks using their existing fiber infrastructure. CoreOptics' 10G and 40G Distortion Tolerant Transponder Modules eliminate the need for Optical Compensators and the respective Second Stage Amplifiers, allowing customers to reduce their first-in deployment cost by up to 30%.
Oree, Inc. develops planar light-emitting diode (LED) illuminations/lights. The company also develops a technology that bridges the gap between chip-on-board and package-on-board LED technology, and illumination applications. Its technology enables the use of LEDs in general lighting, decoration, and LCD panel markets. The company’s technology is also used by general lighting companies and back light manufactures. Oree, Inc. was founded in 2006 and is based in Ramat Gan, Israel with research and development centers in Israel and Germany.

Medi Markt Service Nord & Ost

Acquisition in 2018
Medi Markt Service Nord & Ost stands for a need-and situation-appropriate professional supply of medical aids for over 10 years. Our specialties include incontinence, diabetes, stoma, enteral nutrition, tracheostomy, dressing materials, care products and hygiene and disinfection products.

Summa

Acquisition in 2016
Summa's rich history began in a Gistel, Belgium factory in 1973. The factory was established to assemble high-tech recording devices used in, among other things, the manufacture of precision optical lenses. Summa's evolution into vinyl imaging started in 1987, when it began modifying pen-plotters for use in vinyl-cutting applications. That evolution led to what Summa is today, a recognized global leader in vinyl cutting and imaging equipment for the sign, outdoor advertising and aerospace markets.

Ablynx

Grant in 2014
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Marco Vasco SAS

Series A in 2013
MarcoVasco, (previously known as PlanetVeo) is an online travel agency specialised in organising tailor-made journeys. Founded in 2007 by 3 French entrepreneurs, Marco Vasco quickly became a leader on the online custom holidays market. The company is based in Paris (France) with an office as well in Shanghai (China). The company is profitable since 2010 and our revenues have grown rapidly from 1 million euros in 2008 to 60 million euros in 2013 (organic growth).

Stiplastics S.A.S.

Venture Round in 2018
Stiplastics S.A.S. engages in designing, developing, and manufacturing medical devices for the healthcare industry in France and internationally. It offers distributor pumps, containers, tamper-proof containers, liners for caps, caps, closures, cosmetic spatulas, nozzles and droppers, spoons, IML measuring scoops, measuring spoons, measuring cups, dosing systems, special dosing systems, transportation boxes, and specific packaging products; pharmaceutical packaging products, carrying cases for biological samples, and pillboxes; and more. The company provides its products through its catalog. Stiplastics S.A.S. was founded in 1985 and is based in Beauvoir-en-Royans, France.

CoreOptics

Series C in 2003
CoreOptics is the leading providers of 10G and 40G Distortion Tolerant Transponder Modules and IC solutions for Metro, Regional and Long Haul optical & data networking markets.With a belief that optical communications networks must become open systems that economically transmit information regardless of data rate or fiber types, CoreOptics provides the only field-proven MLSE-based equalization solutions on the market today. This innovative technology helps Tier 1 systems vendors and carriers deploy the next generation of high-performance networks using their existing fiber infrastructure. CoreOptics' 10G and 40G Distortion Tolerant Transponder Modules eliminate the need for Optical Compensators and the respective Second Stage Amplifiers, allowing customers to reduce their first-in deployment cost by up to 30%.

ALT Technologies

Acquisition in 2017
ALT Technologies was incorporated in 1935 and is a leading producer of key airbag components (with a focus on covers, wraps and seals). The company supplies almost all major airbag producers and has multi-annual contracts with them. This means that ALT products can be found in almost all well-known car brands across the globe.

AME

Private Equity Round in 2020
AME is an independent developer and manufacturer of high quality electronic products located in the top technological region.

McPhy

Venture Round in 2013
McPhy Energy S.A. develops and supplies hydrogen production, storage, and distribution equipment for hydrogen energy, zero emission mobility, and industrial hydrogen markets worldwide. The company offers alkaline electrolyzers, including small, medium, and large hydrogen production units; and hydrogen storage solutions. It also designs medium and large hydrogen stations; and integrated hydrogen solutions. The company was founded in 2008 and is based in La Motte, France.

ORMvision

Series B in 2001
Ormvision is a provider of relationship management systems to the telecom industry.

Ablynx

Series B in 2004
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Mackevision Medien Design

Acquisition in 2014
Mackevision Medien Design GmbH is one of the global market leaders in Computer Generated Imagery (CGI). It provides data-based 3D visualization, animation and visual effects. The company designs and produces image and film material, as well as interactive applications in high-end quality.It develops technological solutions for generating images and accompanies the entire CGI process from data preparation to creative design to the finished product.

GreenWatt

Venture Round in 2012
GreenWatt is an established CleanTech company offering full engineering services, covering feasibility study conception, construction and starting up of turn key small scale biogas plants around innovative and unique patented technologies solving all key issues of anaerobic digestion.

Acceo

Acquisition in 2016
ACCEO through its subsidiaries engages in various diversified sectors. It offers elevator engineering, accessibility diagnosis of buildings, and serves hospital markets.

Inside Secure

Series D in 2010
Mobile security and secure transaction offerings to protect critical assets including connected devices, content, services and transactions.

Biom'Up

Series C in 2015
Biom'Up S.A. develops and commercializes hemostatic products based on patented biopolymers. It offers HEMOBLASTTM bellows and its laparoscopic applicators to simplify the surgeons’ practices for open surgical procedures in various specialties, such as cardiac, general and orthopedic, and laparoscopic surgeries. The company markets its products in Europe and the United States. Biom'Up S.A. was founded in 2005 and is based in Saint-Priest, France.

Kinaset Therapeutics

Series A in 2020
Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.

GreenPeak Technologies BV

Series B in 2009
GreenPeak Technologies BV, a fabless semiconductor/system company, develops ultra-low power wireless data communication controller chips for smart home applications and consumer electronics. It provides communication controller semiconductor products and software technologies for smart home data communications; a range of IEEE 802.15.4 and ZigBee silicon solutions; and Senior Lifestyle sensor and cloud based intelligent system technology to enable children and their elderly parents to privately and securely share lifestyle information. The company also offers integration, support, and training services. It markets and sells its products to OEMs and ODMs in the United States, Europe, Asia, and Latin-America. GreenPeak Technologies BV has a strategic partnership with Sensara. GreenPeak Technologies BV was formerly known as Xanadu Wireless BV and changed its name to GreenPeak Technologies BV in 2007. The company was founded in 2004 and is based in Utrecht, the Netherlands with additional offices in Belgium, China, France, the United States, Japan, and Korea. As of April 29, 2016, GreenPeak Technologies BV operates as a subsidiary of Qorvo, Inc.

Arseus Medical B.V.

Private Equity Round in 2017
Arseus Medical B.V. distributes medical equipment and consumables to hospital. Its products include medical devices, disposables, hygiene and disinfection products, medical instruments and small diagnostic materials, lab and testing materials, reagents, catheters, surgery equipment, instruments products, and disposables. Arseus Medical B.V. was formerly known as Omega Medical BV. The company was founded in 2002 and is based in Waalwijk, the Netherlands. Arseus Medical B.V. is a former subsidiary of Fagron NV.

Teads S.A.

Series B in 2015
Teads, founded in 2011, is the inventor of outstream video advertising and the leading native video advertising marketplace. Publishers work with Teads to create new video inventory, monetizing it through programmatic buying, their own sales force, or third parties including Teads Demand. Teads pioneers advertising experiences that respect the user, creating unprecedented levels of premium inventory which previously didn’t exist. Teads has a team of over 600 employees, 100 of which are in the innovation team, across 27 global offices. In May 2017, Teads became part of the Altice Group, a convergent global leader in telecom, content, media, entertainment and advertising.

Proficient Systems

Venture Round in 2003
Proficient Systems is a leading enterprise software company that develops solutions enabling companies to increase revenue and sales productivity. By identifying and connecting online sales opportunities with offline sales and service operations Proficient enables companies to successfully drive new customer acquisition, lead generation and an improved online customer experience. Headquartered in Atlanta, Georgia, Proficient was founded by successful entrepreneur, Gregg Freishtat. Gregg recognized that large enterprises selling complex, consultative products and services, like mortgages or insurance, had made significant investments in their e-business and in their sales and service organizations - but for some reason the two weren't connected. His belief was that if the two were connected, the enterprises would see a significant increase in revenue while delivering superior customer service and a better customer online experience. With this belief in mind, he assembled a group of professionals with decades of experience creating and delivering solutions to large enterprises, to create a strategic business solution to meet these objectives. In October 2000, Proficient was born. Today, organizations are benefiting from Gregg's vision and his ability to create a company to make his vision become a reality.

Nomadesk NV

Series A in 2007
Nomadesk is a European SaaS company, founded in 2004 and focused on Business File Sharing & Synchronization technology.  We are leading developers of cloud software for sharing and synchronizing digital documents, allowing foremost business users to edit, share, synchronize and secure files from anywhere – online and offline! Our company maintains datacenter facilities in Europe (Frankfurt, Amsterdam) and USA (Asheville – NC) for our European and American customers, respectively. ​ Nomadesk mainly targets resellers, service providers and system integrators, who offer the Nomadesk solutions to their clients – usually under a proprietary name, or brand. ​ Nomadesk is part of UnifiedPost, an international BPaaS provider of integrated business process optimisation solutions including complete document delivery and processing solutions, complemented by payment, financial supply chain, credit management and secure e-identity solutions.

Clear2Pay

Venture Round in 2008
Clear2Pay is an innovative payments technology company focused on delivering globally applicable solutions for secure, timely and streamlined payments processing. Clear2Pay's Open Payment Framework (OPF) enables financial institutions to improve internal payments processing efficiencies whilst at the same time providing their clients with better payment services that are faster, with richer payments related information. Clear2Pay's solutions within the Service- Oriented Architecture (SOA) based Open Payment Framework offer financial institutions the ability to process payments through a centralised payments engine that utilises a library of re-useable business services across all payment types. The bank can thus combine new services models with existing infrastructures, thereby protecting previous investments whilst gradually moving to a more modern efficient payments environment.

Santhera Pharmaceuticals

Series C in 2006
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy.

Pronota

Series B in 2009
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

VCST Industrial Products

Acquisition in 2011
VCST is a world-class automotive supplier of precision-machined powertrain and brake components for Automotive OEM’s and Tier 1 suppliers. The company realized a turnover of 169 million euro in 2015 and employs 1250 full time employees. VCST has production facilities in Belgium, China, Germany, Mexico and Romania, with its headquarters located in Belgium.

Oldelft B.V.

Private Equity Round in 2012
Oldelft B.V. manufactures transesophageal echocardiography (TEE) ultrasound transducers, which are used in the adult, pediatric, and neonatal cardio markets for diagnosis and monitoring of the heart. The company offers matrix TEE probe, motorized adult multiplane TEE probe, minimulti pediatric TEE transducer, micromulti TEE probe, and adult multiplane TEE transducer. The company is based in Delft, Netherlands.

Melijoe

Venture Round in 2014
Launched in 2007 by entrepreneur and mother of five Nathalie Christen-Genty, MELIJOE.COM is the world’s premier online fashion e-tailer for children ages 0-16. Featuring the latest in childrenswear trends inspired directly by adult runways, MELIJOE.COM is home to some of the industry’s most sought-after labels in kid’s fashion. MELIJOE.COM is above all an international brand, featuring 100% authentic products, speedy worldwide shipping and a website translated in six languages. Thanks to a developed editorial strategy and magazine-inspired web layout, MELIJOE.COM doubles as a digital news outlet for children’s fashion with Le Magazine, and between exclusive shopping edits, childrenswear news, trend reports and in-house photo shoots, MELIJOE.COM is an extra-large world of digital fashion for the smallest of fashionistas.

Televic N.V.

Acquisition in 2020
Televic, a supplier of high-tech and high-quality communication systems for specific markets such as healthcare, education, the railways sector and the conference market. The existing shareholders remain on board and retain the majority. Diversifying the shareholding will give Televic an additional boost for further worldwide growth and for strengthening its leading role in the sector.

Operator Groep Delft B.V.

Acquisition in 2006
Operator Groep Delft B.V. provides IT outsourcing, IT projects, consulting, and staffing services. The company offers ICT solutions, such as software development, ICT infrastructure, business intelligence, service desk, cloud hosting, online workplace, and application management services. It serves education institutions, government and non-profit organization, business market, and health care sector. The company was founded in 1987 and is based in Delft, the Netherlands.

Ambit Biosciences

Venture Round in 2012
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Contraload

Private Equity Round in 2016
Contraload is a fast growing Pan European company in pooling and rental services for plastic pallets and bins. For more than 10 years CLD has been focusing on plastic load carriers and has close to 1 million assets in its pool, all constantly on the move within the whole of Europe. CLD has a broad range of plastic pallets and IBCs for many different supply chains. Focus lies on the more complex food and FMCG supply chains with demanding and challenging global customers like Unilever, Nestle, Intersnack and many others. CLD helps its customers to meet the high quality and hygienic requirements, avoid foreign body contamination and to connect to suppliers or customers in a cost effective way. “CLD helps you carry the load”, so you can focus on your core business.

ActivePath Solutions Ltd.

Series B in 2011
ActivePath, Inc. develops interactive email and messaging solutions for banks and healthcare providers. It offers ActiveMail, an email banking system. The company also provides card services that deliver paperless e-statements and alerts directly to consumers’ personal email for viewing, ePayment, and live interaction. In addition, it offers E-Business solutions, which create a personal and convenient email channel that enables instant two-way communications and drives online transactions; and support services. The company’s solutions allows banks, card services companies, and brokerage houses to overcome the limitations of email systems, enabling them to capitalize on email as a communications, sales, and marketing channel. It also offers its email solutions for insurance, healthcare, and government organizations. ActivePath was formerly known as PostalGuard Ltd. The company was founded in 2007 and is based in Tel Aviv, Israel with additional office in Deerfield Beach, Florida. As of March 27, 2018, ActivePath Solutions Ltd. operates as a subsidiary of Broadridge Financial Solutions, Inc.

EndoStim, Inc.

Series D in 2016
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.

Camel-IDS

Series A in 2018
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Ablynx

Series A in 2002
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Multiplicom N.V.

Venture Round in 2013
Multiplicom is a Belgian start-up that focuses on molecular diagnostics.

Elixent

Series C in 2005
Elixent, Ltd. supplies reconfigurable arithmetic processors in the United Kingdom. It offers reconfigurable semiconductor intellectual property, a technology that enables user to change the function of a chip even when in use. The company also offers silicon devices and supporting software. In addition, the company provides D-Fabrix, a reconfigurable algorithm processing technology that provides application specific integrated circuit designers with an alternative to fixed function chips; and reprogrammable algorithm solutions for system on chip platforms. Elixent, Ltd. is a spin off of Hewlett-Packard's Bristol Research Laboratories. The company was founded in October 2000 and is based in Bristol, the United Kingdom.

Arrow Therapeutics

Series A in 2000
Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

Nereus Pharmaceuticals

Series A in 2000
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

Accent Jobs for People

Private Equity Round in 2006
ACCENT Jobs For People NV provides temporary employee recruitment and leasing services. It offers jobs in construction, engineering and production, sales and marketing, logistics and distribution, tourism, and other industries. The company was founded in 1995 and is based in Roeselare, Belgium.

Smart Battery Solutions GmbH

Acquisition in 2019
Smart Battery Solutions GmbH develops and manufactures energy storage systems and charging technologies. The company offers unipower/unipower light products, LBP-Xell products, batteries, chargers, and cells. Its products are used for various e-mobility applications, including e-bikes, e-scooters, watercraft, and drones, as well as stationary solutions, such as constant power supply devices. The company was founded in 2010 and is based in Kleinostheim, Germany.

Ambit Biosciences

Series C in 2005
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Endosense

Series C in 2012
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.

RES Software

Venture Round in 2010
We’re the leading digital workspace technology company, and for 15 years we have brought agility and enablement to the workforce while improving IT security. We do this through proactive and self-service access to the apps and services workers need when they need them, in a context that enables them to be most productive. Together, RES products: ~ Empower the workforce through self-service, automated delivery and return of apps and services to each person’s secure digital workspace ~ Enable IT to proactively deliver and revoke access and services whenever employee roles and responsibilities change ~Provide lightweight automation so services and apps no longer need manual delivery ~Allow IT to protect the business with powerful and context-aware security and compliance controls RES boasts numerous patented technologies, faster time to value and superior customer support for more than 3,000 companies around the world. We’re making IT more effective, workers more productive and enterprises more efficient.

Arrow Therapeutics

Seed Round in 1999
Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

Brakel BV

Acquisition in 2015
Brakel has been market leader in the area of daylight access, fire safety and ventilation solutions for more than 35 years, with sales in both Europe and further afield. And we offer integral solutions for all kinds of building types comprising: Daylight Skylights, rooflights, skylights and facades Fire safety SHEV systems, fire alarm systems, detection, compartmentation Ventilation Natural ventilation, controlled natural ventilation Maintenance SHEV and ventilation systems, fire alarm systems, glass constructions

Lampiris

Venture Round in 2013
Lampiris, an independent supplier of gas, green power and energy services such as insulation, furnace maintenance, wood and pellets for heating, and smart thermostats, has been active in the Belgian energy market since 2005. Lampiris, which currently supplies more than a million accounts, is the third-largest supplier in the residential energy market in Belgium.

General Fusion

Series E in 2019
General Fusion Inc. develops commercial Magnetized Target Fusion, a hybrid between magnetic fusion and inertial confinement fusion for transforming energy supply. It also develops scale subsystems, including scale plasma injectors, acoustic drivers, and liquid metal vortex compression tests. The company was founded in 2002 and is based in Burnaby, Canada.

Interwise

Series E in 2004
Interwise provides voice, Web, and video conferencing solutions for the enterprise. The company offers AT&T Connect, an IP software, which is used for voice conferences, Web meetings, virtual training, Web seminars, Webcasts, broadcasts, and recordings. It serves technology, manufacturing, pharmaceutical, insurance, automotive, and retail industries. The company was founded in 1994 and is headquartered in Cambridge, Massachusetts with additional offices in Israel, Japan, the United Kingdom, Switzerland, France, and Germany.

Proficient Systems

Series B in 2005
Proficient Systems is a leading enterprise software company that develops solutions enabling companies to increase revenue and sales productivity. By identifying and connecting online sales opportunities with offline sales and service operations Proficient enables companies to successfully drive new customer acquisition, lead generation and an improved online customer experience. Headquartered in Atlanta, Georgia, Proficient was founded by successful entrepreneur, Gregg Freishtat. Gregg recognized that large enterprises selling complex, consultative products and services, like mortgages or insurance, had made significant investments in their e-business and in their sales and service organizations - but for some reason the two weren't connected. His belief was that if the two were connected, the enterprises would see a significant increase in revenue while delivering superior customer service and a better customer online experience. With this belief in mind, he assembled a group of professionals with decades of experience creating and delivering solutions to large enterprises, to create a strategic business solution to meet these objectives. In October 2000, Proficient was born. Today, organizations are benefiting from Gregg's vision and his ability to create a company to make his vision become a reality.

JenaValve Technology

Series D in 2020
JenaValve's device idea was conceived by Hans-Reiner Figulla, MD, and Markus Ferrari, MD, both cardiologists at the Friedrich Schiller University Clinic, Jena, Germany. In 2006 the company was founded to develop second generation transcatheter aortic valve implantation (TAVI) systems for transapical and transfemoral implantation. At a very early state, it became clear to their research and development as well as clinical teams that safety, precision and durability are key for successful treatment, and ultimately, patient well-being.

ProxiAD

Acquisition in 2013
Established in 1997, Proxiad is a consulting and expertise company in new technologies and information systems. Expert in digital innovation, we develop a unique know-how by accompanying our 710 employees in their professional development so that they are constantly advancing and always at the forefront of technology, in a humanely pleasant and motivating context.

Nereus Pharmaceuticals

Series D in 2007
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

ChemoCentryx, Inc.

Series B in 2004
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

EcoChem International

Acquisition in 2014
EcoChem develops and formulates eco-friendly flame retardants additives, which are mainly used in building & construction, transportation and electronic applications. The company’s products are added to materials such as wood, insulation, textiles or plastics in order to inhibit, suppress or delay flame and smoke production caused by fire. Headquartered in Olen (Belgium), EcoChem operates 2 production facilities located in Willlebroek (Belgium) and in Offenbach (Germany) and is serving clients in 25 countries.

PowerInbox

Series A in 2012
PowerInbox is bringing real-time capabilities to static mail programs. PowerInbox provides an easy to implement solution that combines real-time capabilities, dynamic animation, device and geographic targeting with personalization to ensure higher click through rates. PowerInbox works with existing mail programs and is a platform that marketers, agencies or email service providers can use to deliver creative and effective programs. The company is backed by several leading VCs.

GTX medical

Series A in 2016
GTX Medical is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Endosense

Series C in 2013
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.

Micron Technology, Inc.

Series C in 2009
Micron Ventures is a venture capital arm of Micron Technology, Inc. specializing in early stage investments. It seeks to invest in startups. The firm seeks to invest in technology companies particularly memory solutions, system-level solutions, semiconductor processing solutions, imaging technologies, embedded applications, computing, wireless, and other disruptive semiconductor technologies. The firm prefers to make investments of $100 million for a period of ten years in the portfolio companies. Micron Ventures was founded in 2006 and is based in Boise, Idaho. Micron Ventures operates as an investment arm of Micron Technology, Inc.

Seedcamp

Seed Round in 2011
Seedcamp is Europe's seed fund, identifying and investing early in world-class founders attacking large, global market and solving real problems using technology. Since launch a decade ago Seedcamp has invested in 260+ startups including the likes of fintech unicorn TransferWise along with some of Europe's fastest growing companies Revolut, UiPath, and wefox. Seedcamp fast-tracks a founder’s vision and creates value through immediate access to smart capital, a lifelong community of support and a global network built upon a decade’s experience backing exceptional talent. Seedcamp companies have gone on to raise over $1B+ in further funding from leading investors.

ImCheck Therapeutics SAS

Series A in 2017
ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

NovoPolymers NV

Series B in 2011
NovoPolymers NV develops encapsulant solutions for the photovoltaic market. It offers thermoplastic encapsulant sheets for crystalline silicon based photovoltaic modules; and hydrocarbon thermoplastic elastomer materials. The company was founded in 2008 and is based in Puurs, Belgium.

Endosense

Series B in 2009
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.

Joolz

Private Equity Round in 2016
Joolz designs and manufactures award-winning premium pushchairs. Joolz differentiates itself through the quality of its products and ergonomic design, as well as its unique modern brand and culture. Their stylish and distinctive pushchairs are designed to positively accommodate both child and parent. Joolz goal is to inspire young families to enjoy a positive life, i.e. a sustainable and healthy lifestyle. This aim is reflected in their ergonomic products, re-usable packaging, the Joolz Birth Forest, the partners with whom they work and the steps they take in sustainability.
PamGene has a unique proprietary array-based platform to measure the activities of kinases & nuclear receptors, enabling deeper understanding of drug interactions with these important classes of signalling molecules. PamGene's patented technology finds a wide range of applications including lead identification and optimization, (pre) clinical translational research and biomarker development.

Studiekring BV

Private Equity Round in 2011
Studiekring offers additional guidance for students attending high school and years seven and eight of primary school. Guidance refers to having trouble with homework, scheduling, discipline or motivation towards school.

XL Video

Venture Round in 2011
XL Video, an Ostend-belgim-based global player in the rental of video display systems for concerts, shows and other events. Founded in 1996 and led by CEO and co-founder René de Keijzer, XL Video is an international leading player in the rental of video technology, such as video screens, for major concert tours, trade fairs, TV shows, sports and other events. The group has a large stocks of high-end video technology such as video displays (LED, projection, plasma and LCD), HD camera systems and large trucks with built-in video screens. XL Video also develops and sells its own LED systems (Pixled).

Ubidyne

Series B in 2009
Ubidyne was formed in 2005 to bring its groundbreaking digital Antenna Embedded Radioâ„¢ technology to market. Ubidyne's products will be available from Nokia Siemens Networks as part of their Flexistation product family. The Ubidyne integrated active antenna systems are compatible with CPRI and OBSAI optical interfaces and support current and next-generation standards including GSM, UMTS, HSPA+, and LTE. Ubidyne's micro-radio technology is integrated within wireless antennas and revolutionizes the economics of mobile communications. This eliminates the need for coaxial feeder cables, remote electrical tilt and additional amplifiers on antenna towers and masts. The Ubidyne technology significantly reduces energy consumption while improving radio performance, deployment flexibility, coverage and capacity of mobile communications networks globally.